RxDoctor Payments Data

Bradley Anderson, MD

Ophthalmology · Salt Lake City, UTNPI 1952664260

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,593 of the $4,857 with a category attached, or 74.0%. 22 manufacturers reported payments, led by Kala Pharmaceuticals, Inc. at 26.7% of the total.

$4,857in general payments, 2019–2025

Across 133 payments — averaging $36.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kala Pharmaceuticals, Inc.$1K
  • Alcon$970
  • AbbVie$663
  • Ivantis, Inc$356
  • Sun Pharmaceutical Industries Inc.$337
  • Sight Sciences, Inc.$292
  • plus $945 from 16 others

What the payments were for

  • Consulting fees$1,20025%
  • Food & beverage$3,59374%
  • Gifts$641%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,857 in reported general payments places this provider in the 80th percentile of 191 ophthalmology providers in Utah.

See all ophthalmology providers in Utah

Medicare billing

Part B allowed, 2024
$300,157
Medicare patients
689
Services billed
1,903

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine41$56,365
XiidraLifitegrast31$40,775
LumiganBimatoprost54$39,266
RocklatanNetarsudil Mesylat/Latanoprost16$9,219
CombiganBrimonidine Tartrate/Timolol23$8,198
RhopressaNetarsudil Mesylate11$7,539
Cyclosporine12$5,915
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol30$5,527
Prednisolone Acetate99$3,704
Latanoprost175$2,722
ValacyclovirValacyclovir Hcl13$2,345
Loteprednol Etabonate11$2,271
Brimonidine Tartrate18$1,258
Ketorolac Tromethamine34$906
Dexamethasone Sodium Phosphate19$801

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$663$103,829118 claims
Bausch & Lomb Americas Inc.Xiidra$82$40,77531 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$138$2,27111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 191 ophthalmology providers in Utah.

Other ophthalmology in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →